We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.20% | 1,708.60 | 1,708.60 | 1,708.80 | 1,713.00 | 1,699.40 | 1,701.60 | 11,522,668 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
03/12/2018 22:47 | Thank goodness for guaranteed stops! | toffeeman | |
03/12/2018 22:03 | VS AZN.Pittyfull. free stock charts from uk.advfn.com | tim 3 | |
03/12/2018 21:19 | Rom, read Bloombergs report on this tonight, zejula or whatever its called is no blockbuster, serious side effects, behind the competition and just hasnt taken off, in fact there are serious doubts about parp technology now. I dont need exciting investments i want profitable ones, gsk has been poorly managed for twenty years and so it goes on, share price ever pathetic. | porsche1945 | |
03/12/2018 21:01 | 1518p close stateside | philanderer | |
03/12/2018 20:59 | Am I the only one who thinks that it is bonkers that the market cap of GSK has fallen by 1.5x more that the cost of this acquisition, how can that make any sense? | spyder | |
03/12/2018 20:55 | GSK have said in the RNS they expect to pay the 80p dividend again 'Crown Labs Acquires Rights to Select Brands from GlaxoSmithKline' | philanderer | |
03/12/2018 20:19 | You cannot possibly compare Shire's acquisition of Baxalta to this, Baxalta was larger than Shire. Tesaro is tiny compared to GSK and they are buying it at a price not much less than it was trading at as recently as January. Yes is quite an expensive price in the current market, but this was not an uncontested acquisition and Dr Hal Barron has clearly found enough evidence to convince the board to go for the deal. What are they getting for the money? - a specialist oncology team, proven PARP inhibitor technology, a likely blockbuster drug in Zejula, at least two impressive early stage treatments, as well as an experienced oncology sales team and assets in Boston. | romeike | |
03/12/2018 19:51 | With the Novartis deal and this 4 billion it's a lot of cost. Plus Gsk's debt ...... is the divi in tact ? | mj19 | |
03/12/2018 19:42 | Pharmas are high risk; it is the nature of the sector. If you don't like risk then it is a not a sector for you. It is also one of the most exciting sectors with many many brilliant people. | alphorn | |
03/12/2018 19:27 | just the sort of overpriced lunacy Shire got into and look what happened to them, I think Terry Smith is right, you cant invest in pharma, just too dodgy, nonsense like this all the time, expect more falls, bad deal. | porsche1945 | |
03/12/2018 18:20 | FT "..Liberum said the drug had struggled to carve out a market against competitors such as AstraZeneca and Merck’s Lynparza, saying: “At this point Tesaro looks to be second best in the PARP space and while this can be turned around with expansion in other indications, we have limited evidence thus far that this will be the case.” | philanderer | |
03/12/2018 18:20 | It needs to settle. Tomorrow's another day. | tradermichael | |
03/12/2018 18:18 | Wall St Journal Glaxo investors appeared cool on the deal Monday, with its shares falling almost 8%. Analysts expressed surprise at the deal, pointing to the apparent lack of overlap with Glaxo’s existing cancer pipeline and Zejula’s less favorable side-effect profile. Tesaro’s stock soared nearly 59%. Glaxo’s Chief Scientific Officer Hal Barron said a clinical study that is due to publish results in the first half of next year could expand Zejula’s use to women at an earlier stage of ovarian cancer, boosting sales. Dr. Barron also pointed to a growing body of research suggesting that PARP inhibitors combined with other cancer drugs could prove powerful in treating a range of cancers that exhibit a particular genetic defect. “This is just the tip of the iceberg,” he said. “We’ll start learning about cancers with these defects and how to treat them.” He said Glaxo would test out Zejula in combination with drugs in its own cancer-drug pipeline as well as those under development at Tesaro. full article: | philanderer | |
03/12/2018 17:45 | Market hates the deal, going by the shareprice. | montyhedge | |
03/12/2018 17:44 | I suspect that Hal Baron and Luke Miels had more than a passive involvement in this acquisition and also a better understanding than Monte of what could prove a game changing move for GSK - Emma gets my vote ! | ianood | |
03/12/2018 17:40 | Totally agree, ego-trip to show she can do a large deal. Crazy. | montyhedge | |
03/12/2018 16:36 | Most of the gains achieved since early Feb now undone in one huge gamble. This woman Walmsley is beginning to look like a disaster in the making. She seems hell bent on destroying shareholder's value. Another one of these ego-trippers intent on proving she is a deal-maker whatever the cost. Now a rights or div cut will be on the cards. | bend1pa | |
03/12/2018 16:30 | Romeike - I agree. This is a bold and risky move but is exactly the sort of thing GSK should be doing. Just a shame it has been greeted by a massive negative overreaction | rikky72 | |
03/12/2018 16:30 | Even good companies bought at the wrong price is a bad investment.She's overpaid. | montyhedge | |
03/12/2018 16:25 | Anyone can do deals. It is doing deals at right price she should focus on | watfordhornet | |
03/12/2018 16:20 | ...made me smile too, oh, and I think the markets have over-reacted as usual . | redips2 | |
03/12/2018 16:16 | Paper loss of 35000 pounds for some. | abdullla | |
03/12/2018 16:09 | zho3 Dec '18 - 15:18 - 18468 of 18477 0 2 0 I sometimes need a PARP inhibitor, especially after a few pints of Guinness. Sorry, I'll get my coat. tee hee | davemac3 | |
03/12/2018 15:56 | She won't do that, she wants to prove she can do deals. Walmsley would look stupid. But this is way to expensive deal. 1275p my target. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions